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Background: It is now recognized that preterm infants ≤28 weeks gestation can be effectively supported from the
outset with nasal continuous positive airway pressure. However, this form of respiratory therapy may fail to
adequately support those infants with significant surfactant deficiency, with the result that intubation and delayed
surfactant therapy are then required. Infants following this path are known to have a higher risk of adverse
outcomes, including death, bronchopulmonary dysplasia and other morbidities. In an effort to circumvent this
problem, techniques of minimally-invasive surfactant therapy have been developed, in which exogenous surfactant
is administered to a spontaneously breathing infant who can then remain on continuous positive airway pressure.
A method of surfactant delivery using a semi-rigid surfactant instillation catheter briefly passed into the trachea
(the “Hobart method”) has been shown to be feasible and potentially effective, and now requires evaluation in a
randomised controlled trial.
Methods/design: This is a multicentre, randomised, masked, controlled trial in preterm infants 25–28 weeks
gestation. Infants are eligible if managed on continuous positive airway pressure without prior intubation, and
requiring FiO2 ≥ 0.30 at an age ≤6 hours. Randomisation will be to receive exogenous surfactant (200 mg/kg
poractant alfa) via the Hobart method, or sham treatment. Infants in both groups will thereafter remain on
continuous positive airway pressure unless intubation criteria are reached (FiO2 ≥ 0.45, unremitting apnoea or
persistent acidosis). Primary outcome is the composite of death or physiological bronchopulmonary dysplasia, with
secondary outcomes including incidence of death; major neonatal morbidities; durations of all modes of respiratory
support and hospitalisation; safety of the Hobart method; and outcome at 2 years. A total of 606 infants will be
enrolled. The trial will be conducted in >30 centres worldwide, and is expected to be completed by end-2017.
Discussion: Minimally-invasive surfactant therapy has the potential to ease the burden of respiratory morbidity in
preterm infants. The trial will provide definitive evidence on the effectiveness of this approach in the care of
preterm infants born at 25–28 weeks gestation.
Trial registration: Australia and New Zealand Clinical Trial Registry: ACTRN12611000916943; ClinicalTrials.gov:
NCT02140580.
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The CPAP-surfactant dilemma
In the past two decades, exogenous surfactant therapy
has been a cornerstone of therapy for preterm infants,
and is known to be effective when given prophylactically
in the delivery room, or as a rescue therapy to infants
with established respiratory distress syndrome (RDS) [1].
Its introduction into neonatal practice in the early 1990s
was followed by a considerable decrease in overall neo-
natal mortality rate [2]. With the evolution and refinement
of intensive care for preterm infants, the place of exogen-
ous surfactant therapy is changing. The more widespread
use of nasal continuous positive airway pressure (CPAP)
as a primary means of respiratory support means many
preterm infants with respiratory distress now avoid intub-
ation in the delivery room or in early post-natal life [3-6].
This approach also means delaying or avoiding adminis-
tration of surfactant.
In preterm infants ≤29 weeks gestation, the potential
advantages of early CPAP have been highlighted in large
randomised controlled trials in which treatment with
CPAP from birth, without administration of surfactant,
resulted in fewer ventilator days [7-9] and a trend to-
wards lower risk of bronchopulmonary dysplasia (BPD)
compared to intubated controls [7-9]. In these trials,
however, a large number of infants starting on CPAP ul-
timately required intubation at some time. In the COIN
trial [7], 46% of infants who commenced on CPAP went
on to be intubated in the first 5 days (at a median age of
6.6 hrs), with increasing oxygen requirement and/or re-
spiratory acidosis being the most prominent reasons for
intubation. A further 13% of CPAP-treated infants re-
quired intubation beyond 5 days. In the SUPPORT study
[8] more than 75% of infants randomised to the CPAP
group were intubated at some time, and 67% received sur-
factant. In the VON study [9], 52% of infants commencing
on CPAP without prior surfactant therapy ultimately
required intubation, and 44% received surfactant. These
findings appear to confirm those of earlier observational
studies demonstrating that the most usual cause of early
CPAP failure in preterm infants is unremitting RDS [5,6].
Widespread application of CPAP for initial respiratory
support in preterm infants provides benefit for many,
but is to the detriment of a significant minority of in-
fants destined to go on to fail CPAP because of surfac-
tant deficiency.
CPAP failure and adverse outcome
The group of preterm infants failing CPAP has been in-
completely characterised to date. Our research team has
therefore examined the respiratory course and outcome
for a large cohort of preterm infants initially managed on
CPAP at Royal Hobart Hospital, Hobart (RHH) and Royal
Women’s Hospital, Melbourne (RWH) [10]. We foundthat CPAP failure, defined as need for intubation before
72 hrs, was associated with a high risk of adverse outcome.
Infants who failed CPAP and were intubated < 72 h had a
substantially longer duration of respiratory support than
those in whom CPAP was successful. At 25–28 weeks,
infants failing CPAP had a higher risk of mortality, BPD,
death or BPD, and necrotising enterocolitis (NEC) [10].
As noted by other investigators [6,7], CPAP failure in
the RHH-RWH preterm cohort most often occurred in
the context of unremitting RDS, with the median FiO2 at
intubation being 0.50 in the 25–28 week infants failing
CPAP, and 0.44 in the 29–32 week group [10]. In 23% of
cases a pneumothorax was present at the time of intub-
ation. Hypoventilation (PCO2 > 60 mmHg) was a contrib-
uting factor in only 15% of cases overall [10].
Intubation for surfactant administration
Given the above, it is conceivable that outcomes for pre-
term infants managed initially with CPAP could be fur-
ther improved if the subgroup of infants showing signs
of surfactant deficiency were to receive exogenous sur-
factant. Recognizing the merits of surfactant, especially
when given early [1,11,12], some clinicians choose to in-
tubate infants on CPAP solely for the purpose of admin-
istering surfactant, followed by immediate extubation
and return to CPAP (the “INSURE” approach – intub-
ation, surfactant, extubation) [13-15]. Several clinical tri-
als of this technique have pointed to reductions in the
need for subsequent mechanical ventilation and further
surfactant therapy [16-20], and the risk of pneumothorax
[20]. A more recent study in infants 25–28 weeks gesta-
tion did not find a difference in the primary outcome of
need for mechanical ventilation during the first 5 days,
but 10% of those intubated solely for surfactant adminis-
tration could not be extubated within 1 hour and were
thus deemed to have reached the primary outcome [21].
A larger proportion (17%) were not able to be extubated
in the INSURE group in the recent Vermont-Oxford
Network trial [9].
Intubation solely for administration of surfactant is a
common practice in many Scandinavian units [3,22], but
is less popular elsewhere. Many clinicians consider the
potential benefits of surfactant are outweighed by the
risks of intubation. In the delivery room, intubation can
be complicated by multiple intubation attempts and epi-
sodes of hypoxia [23]. Beyond the delivery room, intub-
ation in preterm infants is now rarely performed without
pre-medicating with narcotics ± muscle relaxants [24],
meaning that there may be a delay in extubation once
surfactant has been administered. Such a delay has been
observed in at least one clinical trial of intubation for
surfactant therapy in infants on CPAP [21]. The use of
sedating premedication also means that where surfactant
is given immediately after intubation, as it most usually
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impair surfactant distribution. Experimental data suggest
that surfactant administration in a spontaneously breath-
ing subject results in more effective dispersion and greater
tissue incorporation of phospholipid [25].
Minimally-invasive surfactant therapy
In view of the difficulties associated with intubation for
surfactant delivery, less invasive means of delivering surfac-
tant have been pursued. Several techniques of “minimally-
invasive surfactant therapy” (MIST) have been described in
which surfactant is delivered without tracheal intubation,
including nasopharyngeal instillation [26], laryngeal mask
placement [27] and aerosolisation [28]. None of these
methods appears ready for clinical application on a wider
scale at present. Another method of MIST in which the
trachea is catheterised with a feeding tube has been re-
ported [29-32]. The technique involves insertion of a 5
French gauge feeding tube into the trachea with Magill’s
forceps. Surfactant is then administered over 1–5 minutes,
and the catheter thereafter removed. A randomised con-
trolled trial of MIST using this technique (the AMV trial)
has recently been conducted in infants 26–28 weeks gesta-
tion having FiO2 > 0.30 in the first 12 hours [33]. Com-
pared to controls, surfactant-treated infants had a lower
rate of subsequent mechanical ventilation (28% vs 45%);
no difference in the rate of pneumothorax or other ad-
verse events was noted. A further trial comparing this
method of MIST with standard intubation in very preterm
infants (23–26 weeks gestation) has now been completed,
and the results are awaited.
An alternative approach in which a flexible feeding tube
is passed through the vocal cords without using Magill’s
forceps has recently been reported [34]. Surfactant deliv-
ery with this method was compared with INSURE in in-
fants <34 weeks gestation, with the finding of a reduction
in early mechanical ventilation, and a decreased incidence
of BPD. This method would amount to a procedural chal-
lenge for most practitioners, and is thus unlikely to be
widely adopted.
The “Hobart method” of MIST
Surfactant instillation by flexible feeding tube has several
technical difficulties that may limit its widespread appli-
cation. Clinicians who solely practice oral intubation will
be unfamiliar with Magill’s forceps, and may find them
cumbersome and hard to use. Additionally, the highly
flexible feeding tube may on occasions be difficult to in-
sert through the vocal cords, and also difficult to maintain
in position once inserted. For these reasons, and with the
recognition of the potential benefits of MIST, our research
group has developed an alternative and novel MIST tech-
nique using a narrow bore vascular catheter (16 gauge
Angiocath, Product No. 382259, Becton Dickinson, Sandy,UT, USA) [35]. This catheter has an external diameter of
1.7 mm, and a length of 135 mm, and is made from fluori-
nated ethylene propylene polymer. It has the dual proper-
ties of sufficient stiffness to allow guidance towards and
beyond the vocal cords, and sufficient elasticity and soft-
ness to avoid damage to the vocal cords and other vital
structures. This catheter can be advanced through the
vocal cords under direct vision using a laryngoscope, with-
out the need for Magill’s forceps. A curvature in the cath-
eter can be fashioned if desired to facilitate placement.
Surfactant can then be administered in one or several
boluses, and respiratory support continued with nasal
CPAP. A video of the technique can be accessed at the
OPTIMIST-A trial website (http://www.menzies.utas.
edu.au/optimist-trials).
Clinical experience with the Hobart method
A preliminary evaluation of the Hobart method of MIST
was conducted at RHH [35], and a two-site feasibility
study was undertaken at RHH and RWH [36]. In the ini-
tial study at RHH, MIST was performed in 25 infants, of
gestational age range 25–34 weeks and birth weight
range 500–3000 g [35]. The MIST procedure was per-
formed in the delivery room in 2 cases, and after arrival
in the Neonatal Intensive Care Unit (NICU) in 23. No
pre-medication was used. Surfactant (Curosurf, Chiesi
Farmaceutici, Parma, Italy) was delivered at a dosage of
approximately 100 mg/kg, given in 1 or 2 boluses. The
surfactant was successfully administered in every infant,
with two attempts at catheterisation needed in 9 (35%).
Brief bradycardia (heart rate <100 beats per minute) was
noted in 11 infants (44%), usually contemporaneous with
insertion of the laryngoscope blade, and in all cases self-
resolving within 10 seconds. Positive pressure inflations
were required after surfactant administration in 11 in-
fants (44%).
The further feasibility study of the Hobart method of
MIST enrolled 61 infants of 25–32 weeks gestation [36].
Eligibility for MIST was based on the need for CPAP pres-
sure ≥7 cm H2O and FiO2 ≥ 0.30 (25–28 weeks) or ≥0.35
(29–32 weeks). At RHH, 3 infants in the 25–28 week
gestation group were treated with FiO2 < 0.30; each had
a CPAP pressure of 8 cm H2O and signs of respiratory
distress. Overall, the 25–28 week group received MIST
at a mean age of 3.5 ± 3.5 hrs (mean ± SD), and the 29–32
week infants at 10.8 ± 7.5 hrs. Surfactant was successfully
administered in all cases, with two catheterisation at-
tempts required in 20%. Positive pressure inflations by
mask were used in 39% of infants prior to reinstitution
of CPAP.
Respiratory course and outcomes in infants treated with
MIST have been compared with like-gestation historical
controls achieving the same CPAP and FiO2 thresholds
(data from the RHH-RWH preterm CPAP cohort). Within
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to those treated with MIST in terms of median gestation,
birth weight, exposure to antenatal corticosteroids, mode
of delivery and Apgar score at 5 minutes. Several potential
benefits of MIST were identified. FiO2 was more rapidly
weaned in surfactant-treated infants than controls in the
first 72 hrs. Need for intubation <72 hrs was diminished
after MIST, most notably for infants at 25–28 weeks gesta-
tion (OR 0.21, 95% CI 0.083-0.55), but with a strong trend
in the same direction in the 29–32 week group (odds ratio
0.34, 95% CI 0.11-1.06). Duration of oxygen therapy was
reduced in infants treated with MIST at all gestations.
The need for further randomised controlled trials of MIST
The findings of the evaluation of MIST using the Hobart
method, coupled with the clear evidence that CPAP fail-
ure occurs largely because of unremitting RDS and is
associated with adverse outcomes, have been the genesis
of the OPTIMIST-A triala. There is considerable scien-
tific justification for this trial, with strong data in sup-
port of: a) the poor outcome for those failing CPAP, b)
the capacity to identify such infants early, c) the potential
for MIST to alter the outcome in such infants, and d) the
potential benefits of surfactant delivery in the spontan-
eously breathing infant [25]. It is thus appropriate to sub-
ject MIST to the highest level of scientific scrutiny in the
form of a randomised controlled trial.
Important considerations in trial protocol development
Enrolment criteria
Not all preterm infants 25–28 weeks gestation managed
on CPAP from the outset stand to benefit from surfactant
administration with a minimally-invasive technique. Some
have minimal or mild RDS, and are well supported by
CPAP alone. For MIST to be of value, it must be coupled
with early and accurate selection of infants at greatest risk
of failing CPAP. In this regard, several indicators previ-
ously put forward have been rejected: a) radiological
scores [6], which are confounded by variability of X-ray
technique and subjectivity of interpretation, b) func-
tional surfactant assays [37,38], which require specia-
lised equipment and training, c) indices of oxygenation
based on arterial pO2 [6], which are impractical because
so few infants on CPAP have arterial lines in situ, and d)
Silverman clinical scores, which will vary considerably
depending on the CPAP pressure level.
Using data from the RHH-RWH preterm CPAP co-
hort, we sought a bedside predictor of early CPAP failure
in the early post-natal period in infants 25–28 weeks
gestation. In a logistic regression model incorporating
demographic variables, FiO2 and CPAP pressures, by far
the strongest predictor of later need for intubation was
the highest FiO2 in the first 2 hours. Addition of CPAP
pressure improved the goodness of fit only slightly (R20.5 vs 0.45). A similar regression analysis by De Jaegere
et al. in infants <30 weeks gestation found FiO2 by
2 hours to be the most influential variable in prediction
of later intubation [39]. Area under the receiver operat-
ing characteristic curve for prediction of CPAP failure
using FiO2 was 0.83 in the RHH-RWH preterm CPAP
cohort and 0.84 in the study of De Jaegere et al. [39]. On
this basis, and in recognition of the need for simplicity
in framing the entry criteria, highest appropriate FiO2 has
been chosen as an entry criterion for the OPTIMIST-A
trial. The FiO2 threshold of ≥0.30 is the same as that used
in the AMV trial, and in our preterm CPAP cohort pre-
dicted intubation <72 hrs with a sensitivity of 83% and
positive predictive value of 60%. Infants achieving this
threshold in the first 2 hrs had a relatively high likelihood
of later intubation (OR 5.6, 95% CI 1.7-18).
Surfactant dosage
Standard surfactant dosage for preterm infants with RDS
ranges from 100 to 200 mg/kg. At least when using
Curosurf, there is some evidence that a dose of 200 mg/
kg reduces the need for re-treatment [40]. This dose has
been used in several studies of surfactant administration
by brief intubation in infants <30 weeks gestation [17,21].
In the feasibility studies of the Hobart method of MIST, 7
infants 25–28 weeks gestation received a surfactant dos-
age of 200 mg/kg. No treatment complications were noted
in those receiving the larger dose, their oxygenation re-
sponse was more pronounced and prolonged, and none
required intubation <72 hrs [36]. These observations,
coupled with the wider experience, provide the basis
for the 200 mg/kg surfactant dosage stipulated in the
OPTIMIST-A trial.
The surfactant delivery catheter
The surfactant delivery catheter used to date in the studies
of the Hobart MIST method has been the 16G Angiocath
(Becton Dickinson, Sandy, UT, USA). These studies re-
vealed no major deficiencies with the catheter for the pur-
pose of surfactant instillation, other than the need to mark
the depth of insertion with a marker pen. The 16G Angio-
cath will thus be used in the OPTIMIST-A trial until a
purpose-built surfactant delivery catheter with very similar
design features becomes available.
Method of laryngoscopy
In the initial feasibility studies at RHH and RWH, direct
laryngoscopy for tracheal catheterisation has been per-
formed using a standard laryngoscope with a Miller 0 or
00 blade. During further evaluation, tracheal catheterisa-
tion has been successfully undertaken using a Glidescope
Cobalt AVL video laryngoscope (Verathon Medical,
Burnaby, Canada) with a size 0 blade. The use of this
video laryngoscope is permitted in the OPTIMIST-A
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to assist in guiding the catheter through the vocal cords.
Premedication
Experience from the RHH-RWH feasibility studies sug-
gests that the MIST procedure is generally well-tolerated
without any premedication. Initial evaluation of the Co-
logne method reported the use of atropine at a dose of
25 μg/kg [30], although this has since become optional
[32]. In the OPTIMIST-A trial premedication with atro-
pine is at the discretion of the OPTIMIST Treatment
Teams. Use of oral sucrose is encouraged. Narcotic anal-
gesics or other sedating medications are not permitted.
Intubation criteria
Criteria for intubation of infants on CPAP have been
stipulated in the OPTIMIST-A trial, based on experience
from previous studies, examination of the RHH-RWH
data, and knowledge of local practices. Enrolled infants
will be intubated if persistently requiring an FiO2 of 0.45.
As with previous trials [7,8], other intubation criteria apply
in the event of apnoea, persistent acidosis or need for an
intervention.
Primary outcome and sample size
An initial randomised controlled trial of MIST had as its
primary outcome the need for intubation and mechan-
ical ventilation, and found a reduction in this outcome
after MIST [33]. Whilst avoidance of mechanical ventila-
tion is a worthy goal, it would seem that if infants are to
undergo direct laryngoscopy and tracheal surfactant ad-
ministration, it should be with the aim of producing a
more tangible benefit than simply reducing the intubation
rate. The choice of primary outcome in the OPTIMIST-A
trial reflects this. The primary outcome is the composite
of death or BPD, which according to our experience in
25–28 week infants (RHH-RWH data) currently occurs in
53% of those failing CPAP and 38% of those reaching the
enrolment threshold. The OPTIMIST A trial has been
powered to detect a reduction by one-third in this out-
come (from 38% to 25%). Such a reduction appears to be
a realistic target given that the rate of death or BPD in
those succeeding on CPAP (not intubated in the first
72 hours) is 14%. It would also represent a major improve-
ment in outcome for the 25–28 week group overall.
With the publication of feasibility studies and small
clinical trials, there is a possibility that surfactant ad-
ministration via MIST could become popular in the
neonatal community before being adequately scruti-
nised. The OPTIMIST-A trial offers timely and rigorous
evaluation of MIST, and we believe it will be a definitive
trial in shaping the future approach to this therapy. For
this reason we have calculated the sample sizes for the
OPTIMIST-A trial based on 90% power.Trial aim
To evaluate in a randomised controlled trial the efficacy
of surfactant delivery via a minimally-invasive technique
in preterm infants 25–28 weeks gestation with RDS
treated with CPAP.
Trial hypothesis
That early surfactant administration via a minimally-
invasive technique to preterm infants on CPAP results
in a lesser duration of mechanical respiratory support,
and a higher incidence of survival without BPD.
Methods/Design
Trial design
Multicentre, randomised, masked, parallel controlled trial.
Participating centres
The following centres are actively recruiting for the trial:
Australia: Royal Hobart Hospital, Hobart; Royal
Women’s Hospital, Melbourne; Monash Medical
Centre, Melbourne; Women’s and Children’s Hospital
Adelaide.
New Zealand: Auckland City Hospital, Auckland;
Middlemore Hospital, Auckland.
United States: Evanston Hospital, Evanston, IL.
Turkey: Zekai Tahir Burak Hospital, Ankara.
The following centres have committed to joining the
trial:
Australia: Mercy Hospital for Women, Melbourne.
New Zealand: Dunedin Hospital, Dunedin.
Israel: Ziv Medical Center, Tsfat; Bnai Zion Medical
Center, Haifa.
United Kingdom: Southampton University Hospital,
Southampton; Southern General Hospital, Glasgow;
Royal United Hospital, Bath; University Hospital of
Wales, Cardiff.
The Netherlands: University Medical Center,
Groningen.
Poland: Poznań University of Medical Sciences,
Poznań; Medical University of Łódź, Łódź;
Polish Mothers’ Memorial Hospital, Łódź; SPZOZ
Provincial Hospital, Bydgoszcz.
Italy: San Gerardo Hospital, Monza; Ospedale
Maggiore Policlinico, Milano.
Slovenia: University Medical Centre, Ljubljana.
Greece: Aristotle University of Thessaloniki,
Thessaloniki.
Turkey: Uludag University Hospital, Bursa.
United States: Yale-New Haven Children’s Hospital,
New Haven, CT; Children’s Hospital of Georgia,
Augusta, GA; Cooper University Hospital, Camden,
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Allen Health Care, Burlington, VT; Beth Israel
Deaconess Medical Centre, Boston, MA; West Virginia
Health Science Center, Morgantown, WV; University
of Southern California, Los Angeles, CA; Oklahoma
University Health Science Center, Oklahoma, OK;
Westchester Medical Center, Valhalla, NY.
Study population
Preterm infants of gestation 25 weeks 0 days to 28 weeks
6 days who are inborn and admitted to the NICU of a par-




1. Requiring CPAP or nasal intermittent positive
pressure ventilation (NIPPV) because of respiratory
distress.
2. CPAP pressure of 5–8 cm H2O and FiO2 ≥ 0.30.
3. Less than 6 hours of age.
4. Agreement of the Treating Physician in charge of
the infant’s care.
5. Signed parental consent.
Exclusion criteria
1. Previously intubated, or in imminent need of
intubation because of respiratory distress, apnoea or
persistent acidosis.
2. Congenital anomaly or condition that might
adversely affect breathing.
3. Identifiable alternative cause for respiratory distress
(e.g. congenital pneumonia or pulmonary hypoplasia).
4. Lack of availability of an OPTIMIST treatment
team.
Consent
Written parental consent must be obtained prior to ran-
domisation by the treating clinicians. A plain language
document outlining the rationale for the study is given to
the parents. Consent should be obtained prenatally where
possible, in which case the infant will only be enrolled
after birth if all inclusion and no exclusion criteria were
fulfilled. In all cases, written consent is obtained using a
specifically-designed consent form.
Randomisation
Once consent has been obtained and all entry criteria
are met with no exclusions, the infant is randomised by
the OPTIMIST Treatment Team, after handover of care
from the treating clinicians. Enrolled infants are rando-
mised into “surfactant via MIST” and “standard care”(sham treatment) groups, with an allocation ratio of 1:1,
using a web-based randomisation procedure that requires
confirmation of eligibility criteria and consent before re-
vealing the randomly determined allocation. The random-
isation is in randomly permuted blocks of variable length,
stratified by study centre, and by gestational age. For the
OPTIMIST-A trial there are two gestational age strata
(25–26 weeks and 27–28 weeks). Twins and higher order
multiples are randomised independently. Infants who are
unstable and in need of immediate intubation should not
be randomised, even if consent has been obtained; such
infants will not be considered to have been enrolled.
Masking
In order to mask the group allocation from the treating
clinicians, an OPTIMIST Treatment Team is mobilised to
perform the randomisation and intervention. This team
consists of a neonatologist, senior neonatal trainee or neo-
natal nurse practitioner, and a neonatal nurse, none of
whom are currently involved in the infant’s care. Their
role is to obtain the randomisation, and then within 1 hour,
after screening the infant as effectively as possible from
the treating clinicians, to administer the intervention (sur-
factant via MIST or sham treatment) in accordance with
the randomised allocation. Their activities, including re-
moval of surfactant from the medication refrigerator,
movement and speech within the screened space, and ma-
nipulation of the infant, should be such that the treating
clinicians cannot discern which intervention is received.
All treating clinicians are made aware that the OPTIMIST
Treatment Team will be concealing treatment allocation
by performing a sham procedure on those infants ran-
domised to standard care. The time taken to perform
the intervention should be the same regardless of treat-
ment allocation, and the infant is returned to the pre-
intervention CPAP settings prior to removing the screens.
A survey of clinical staff is being conducted after each
OPTIMIST intervention in order to assess the success
of masking.
Members of OPTIMIST Treatment Teams at all insti-
tutions undertake not to reveal the allocation group of
randomised infants.
Intervention
The intervention is performed in the NICU of participat-
ing centres. Prior to intervention, all neonates must be
stable on CPAP delivered by prongs or mask. An intraven-
ous cannula should be in situ. It is desirable that a blood
gas analysis (arterial or capillary) is performed before
intervention, although this is not mandatory. A chest X-
ray is recommended to confirm the diagnosis of RDS, and
to exclude other causes of respiratory distress.
Having been briefed on the current condition of the in-
fant, the OPTIMIST Treatment Team screens the infant
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fant is then randomised, and the allocated intervention
carried out as soon as possible (maximum 1 h after ran-
domisation). Pre-intervention observations are recorded.
The Treatment Team takes a labelled box containing full
or empty surfactant vials from the OPTIMIST canister
in the medication refrigerator. This canister must not be
accessed by any other person other than the NICU
pharmacist responsible for replenishing the stock of sur-
factant, which is supplied specifically for the study.
Intervention – surfactant administration via MIST
The following protocol is used for performing MIST:
Preparation
1. Prepare the 16G Angiocath by marking a point
indicating the desired depth of insertion beyond the
vocal cords with a marker pen. The required depth
is as follows: 25–26 weeks: 1.5 cm; 27–28 weeks
2.0 cm. Some investigators may find that tracheal
catheterisation is facilitated by fashioning a slight
anterior curve in the catheter.
2. Draw up the surfactant (Curosurf™, Chiesi
Farmaceutici, Parma, Italy) in a 3 or 5 mL syringe.
The surfactant dose is 200 mg/kg (2.5 mL/kg). Draw
up an additional 0.5 mL of air into the syringe,
taking account of the dead volume of the instillation
catheter (~0.3 mL).
3. Optional: administer atropine 20 μg/kg
intravenously.
4. Disconnect standard monitors and connect the
infant to the OPTIMIST oximeter (supplied to each
centre)
5. The infant can be swaddled and oral sucrose
administered as part of standard procedural nursing
care.
Performing MIST
1. Position the infant as for a standard intubation
procedure.
2. If possible, the laryngoscopy and tracheal
cannulation should be performed with the CPAP
prongs remaining in situ. An alternative which may
improve the view of the vocal cords is to remove the
CPAP prongs and apply CPAP by mask until the
laryngoscopy commences.
3. Perform direct laryngoscopy using a standard
laryngoscope and blade. Alternatively, use the
Glidescope Cobalt AVL video laryngoscope and size
0 stat.
4. Insert the surfactant instillation catheter through the
vocal cords to the desired depth, and hold it inposition at the lips. The laryngoscope should then
be removed.
5. Connect the surfactant syringe to the catheter hub,
and instil the surfactant in 2–4 boluses over 15–30
seconds.
6. Once the surfactant is instilled, immediately remove
the instillation catheter and apply CPAP by prongs
or facemask.
7. If on the first attempt catheterisation of the trachea
is not possible within 20–30 seconds, remove the
laryngoscope, allow recovery on CPAP as required,
and then attempt tracheal catheterisation once
again. The maximum number of catheterisation
attempts should be 3, after which the procedure
should be abandoned.
After MIST
1. Once heart rate, SpO2 and respiratory effort are
close to baseline values, restore the infant to their
previous position, and re-establish CPAP with the
same device and settings as prior to surfactant
instillation.
2. Details of the procedure are recorded on a data form
specifically related to the intervention. This form is
then removed from the bedside by the Treatment
Team, and sent to the OPTIMIST Data
Management Centre in electronic format. A copy of
the form should be placed in locked cabinet away
from the clinical area.
3. Observations are recorded 5 minutes post-
intervention, after which the OPTIMIST oximeter is
disconnected and normal monitoring resumed.
4. All items that could reveal the treatment allocation
to the treating clinicians should be cleared from
the bedside.
Because of the novelty of the MIST technique, OPTI-
MIST Investigators are given the opportunity to practise
the technique on an intubation mannequin during an
OPTIMIST training workshop. Experience from the feasi-
bility studies at RHH Hobart and RWH Melbourne indi-
cates that neonatologists and neonatal fellows are highly
likely to succeed in tracheal catheterisation from the out-
set, although two attempts at catheterisation may be re-
quired until familiarity with the technique is gained.
Intervention – standard care (sham MIST procedure)
The following protocol is used in the standard care group:
1. Position the infant as for a standard intubation
procedure. This is the only actual intervention for
babies randomised to standard care. CPAP is not
interrupted at any time in this group. The
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monitoring disconnected as for the MIST
procedure.
2. Simulate the MIST procedure in terms of time taken
and movement and communication within the
screened area.
3. After the procedure, restore the infant to their
previous position, and ensure the CPAP settings are
the same as prior to the sham procedure.
4. Record the time of the sham intervention on the
OPTIMIST Intervention Form, remove the form
from the bedside, and send to the Data Management
Centre, retaining a copy, exactly as described for the
MIST procedure above.
Management immediately after MIST
Once the MIST procedure or sham procedure is com-
pleted, the screens around the infant are removed, and
care of the infant returned to the treating clinicians. For
all infants, attention is drawn to the possible need to re-
duce the FiO2 so as to keep SpO2 in the target range.
An entry is made on the drug chart to indicate the
timing of the OPTIMIST study intervention. A card is
placed at the bedside indicating that the infant has been
enrolled in the trial, and displaying the intubation cri-
teria. Post-intervention observations are recorded by the
treating clinicians at 4 hours.
Post-MIST investigations
A blood gas analysis (arterial or capillary) should be per-
formed at 4 hours post-intervention, or earlier if clinic-
ally indicated.
Post-intervention management
Other than the requirement to adhere to intubation cri-
teria in the first week, and in some cases perform a
room air trial at 36 weeks corrected gestation, manage-
ment of enrolled infants after intervention is at the dis-
cretion of the clinical team. Titration of CPAP pressure
according to work of breathing and oxygen requirement
is encouraged. Maximum acceptable CPAP pressure is
8 cm H2O. NIPPV (bi-level CPAP) is allowable. Adjust-
ment of FiO2 should be so as to target an SpO2 range
appropriate for gestation and post-natal age. Prophylac-
tic caffeine therapy would be expected in all infants [41].
Criteria for intubation
Infants should be intubated and ventilated if, and only if,
they fulfil any of the following criteria:
1. FiO2 ≥ 0.45. To qualify for intubation, the FiO2 must
be sustained at intubation level for at least
15 minutes, and all other aspects of CPAP
management must have been optimised (includingprong size and position, and minimisation of CPAP
pressure leak).
2. Apnoea unresponsive to caffeine therapy and
stimulation, which is either frequent (6 episodes in
6 hours requiring vigorous stimulation), or severe
(more than one episode requiring positive pressure
ventilation)
3. Persistent respiratory acidosis with pH < 7.20 and
PCO2 > 65 mm Hg on two blood gas samples at
least 30 minutes apart, or metabolic acidosis
refractory to treatment
4. Need for an anaesthetic or an intervention requiring
intubation
Note that these criteria apply only during the first week
of life, and only for the first episode of intubation.
Once intubated, surfactant therapy can be given, at the
discretion of the treating clinicians. There is no likelihood
of harm if a further dose of surfactant is given less than
6 hours after surfactant administration via MIST. Thus the
treating clinicians remain masked in this circumstance.
Assessment of BPD at 36 weeks corrected gestational age
Incidence of BPD based on oxygen requirement at 36 weeks
corrected gestational age is variable within units in the
Australian and New Zealand Neonatal Network (ANZNN),
certainly in part due to variability in approach to oxygen
therapy amongst units. Given the primacy of BPD as an
outcome in the OPTIMIST-A trial, a standardised ap-
proach to its recognition has been incorporated into the
trial design, based around the National Institute of Child
Health and Disease consensus panel definition of “physio-
logical BPD” [42]. On or shortly after 36 weeks 0 days cor-
rected gestation, infants not requiring respiratory support
(intubation/CPAP/HFNC ≥ 2 L/min) but receiving oxygen
therapy with an FiO2 of less than 0.30 have a trial of room
air. For infants on nasal cannula oxygen the “effective
FiO2” is determined using the Benaron-Benitz formula
[43], currently available as on online calculator (http://
pub.emmes.com/study/rop/stop-js.html). Those with an
FiO2 < 0.30 have an air trial involving stepwise FiO2 re-
ductions 5 minutes apart until either room air is being
administered or SpO2 is no longer within the target range.
Based on current evidence, the minimum acceptable SpO2
reading for this trial is 91% [44]. A successful room air
trial is defined as SpO2 readings ≥91% for 30 minutes in
room air with nasal prongs removed [42]. Oxygen therapy
can thereafter be reinstituted if deemed necessary by the
treating clinicians.
Infants receiving HFNC therapy with FiO2 0.21 and
flow < 2 L/min also have a room air trial as above with
the nasal prongs removed.
Infants requiring respiratory support, and those failing
the room air trial, are deemed to have physiological
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nosed if oxygen and/or respiratory support (intubation/
CPAP/HFNC ≥2 L/min) is being administered for any
portion of the day at 36 weeks and 0 days corrected ges-
tational age.
Severity of BPD is categorised according to the con-
sensus definitions [42]:
Mild BPD: need for oxygen at 28 days but not at
36 weeks corrected gestation.
Moderate BPD: need for oxygen at 28 days and
continued oxygen requirement at 36 weeks (confirmed
by room air trial), with FiO2 < 0.30.
Severe BPD: need for oxygen at 28 days, and at
36 weeks an oxygen requirement with FiO2 ≥ 0.30 and/
or need for positive pressure support (intubation,
CPAP, HFNC ≥2 L/min).
Data collection and management
Within the OPTIMIST Investigator Team at each site,
nominated personnel (e.g. Unit Data Collectors, Unit
Research Nurses) collect data and enter it onto hard
copy and/or electronic forms, as available. Data manage-
ment is coordinated from the Clinical Epidemiology and
Biostatistics Unit (CEBU) at the Murdoch Childrens
Research Institute (MCRI), using a web-based database
management system.
Data collection in hospital
Basic demographic, perinatal, and clinical data, as well
as in-hospital outcomes, are collected prospectively for
each patient, starting at enrolment. The data are entered
on a hard copy clinical report form. Data pertaining to
the MIST procedure are collected by the OPTIMIST
Treatment Team, on a separate randomisation and
intervention form. This form is not seen by other clin-
ical or research staff. Once filled in, it is sent electronic-
ally to CEBU at MCRI. Information recorded includes
the number of attempts required to catheterise the tra-
chea, the total time taken, the lowest heart rate noted
during the MIST procedure and time for restoration of
heart rate above 100 beats per minute, the lowest SpO2
noted and time for restoration of SpO2 above 80%, and
the need for and duration of positive pressure inflations
by mask.
Data on heart rate, CPAP pressure, FiO2, and SpO2 prior
to, and at four hours after intervention are collected,
along with the results of pre- and post-intervention
blood gas analysis.
Follow up
Each infant will have a full clinical and neurological
assessment performed at 2 years by a developmental
paediatrician blinded to the initial randomisation.Psychometric testing will be performed by a trained
practitioner using the Bayley III Scales of Infant Devel-
opment (or equivalent). Hospitalisation history in the
first two years will be documented at this visit.
Outcome variables
Primary outcome
Incidence of composite outcome of death or physiological
BPD [42].
Secondary outcomes
A range of standard clinical outcomes pertaining to the
first hospitalisation are being ascertained in trial partici-
pants. These are shown in Table 1. Additionally, data are
being collected in the intervention group relating to the
applicability and safety of the Hobart method (Table 2).
For this purpose, data from the study oximeter are used
alongside data recorded manually by the Treatment Team.
Finally, longer term outcomes are being evaluated at two
years corrected age as part of the OPTIMIST-A follow-up
study. This study will have its own protocol and funding
stream. Selected outcomes from this study are shown in
Table 3.
Statistical analysis and reporting
Statistical analysis
Data handling, verification and analysis for the OPTIMIST-
A trial are being performed by CEBU at MCRI. Statistical
analysis will follow standard methods for randomised
trials and the primary analysis will be by intention to
treat. For dichotomous outcomes, including the primary
outcome in OPTIMIST-A, proportions will be com-
pared using the odds ratio with 95% CI, obtained from a
logistic regression analysis with adjustment for the strata
(defined by centre and gestational age category) used in
the randomisation. Continuous outcomes will be com-
pared using differences between mean values, estimated
from normal linear regression models with the same strati-
fication adjustments. Secondary analyses will use expanded
regression models to explore potential confounding effects
of chance imbalances between arms in birth weight, gen-
der, antenatal steroids, or mode of delivery. In further sec-
ondary analysis, we will explore evidence for heterogeneity
of effects between the two gestational age strata in the trial,
using interaction tests and subgroup analyses.
Data reporting and manuscript preparation
A clinical study report will be generated from the Data
Management Centre. This document will, after approval
by the Trial Steering Committee, form the basis of con-
ference presentations and manuscripts for publication.
In all cases data reporting will adhere to the CONSORT
guidelines. Responsibility for manuscript preparation will
rest with the Trial Steering Committee. Authorship will
Table 1 Clinical outcomes during first hospitalisation
Physiological BPD [42] Duration of intubation (all episodes)
Clinical BPD (oxygen or positive pressure support at 36 weeks corrected
gestation) [45]
Duration of CPAP/NIPPV (all episodes)
Mild/moderate/severe BPD [45] Duration of intubation and CPAP
Death Duration of HFNC, minimum flow rate 2 L/min
Death or BPD (clinical definition) Duration of respiratory support
Intraventricular haemorrhage (IVH) (all grades) Duration of oxygen therapy
IVH grades III and IV [46] Requirement for oxygen at home
Cystic periventricular leukomalacia Length of stay in intensive care
Retinopathy of prematurity (ROP) > stage II Length of hospital stay
Major morbidity (any of IVH grade III or IV, periventricular leukomalacia,
ROP > stage II, physiological BPD) [47]
Total hospital billings
Death or major morbidity Calculated cost of hospitalisation
NEC (Modified Bell stage 2 or greater) [48] Pneumothorax requiring drainage
NEC or spontaneous intestinal perforation requiring surgery Pulmonary haemorrhage
Requirement for intubation < 72 h Patent ductus arteriosus (PDA) requiring anti-prostaglandin therapy
Requirement for intubation at any time PDA requiring ligation
Need for additional surfactant therapy Late onset sepsis (positive bacterial or fungal culture from a
normally sterile site)
Overall number of surfactant doses (including that given by MIST) Time to regain birth weight
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the OPTIMIST-A Investigators.Sample size
In the RHH-RWH CPAP study, amongst infants of 25–
28 weeks gestation the proportion positive for the out-
come of death or BPD was 53% in those failing CPAP
and 38% in those reaching the OPTIMIST-A enrolment
threshold in the first 2 hours. A reduction by one-third
in the proportion of infants with this outcome (i.e. from
38% to 25%) would be a major advance in care for this
patient group, relieving the burden at both individual
and NICU levels. Detection of a reduction of this magni-
tude with 90% power and α = 0.05 (two-sided) would re-
quire 297 subjects per arm [49]. An allowance has been
made for withdrawal of 2% of subjects post-recruitment.
The number of subjects to be randomised in each arm is
thus 303, for an overall total of 606.Table 2 Applicability and safety outcomes in infants




Duration of hypoxaemia (SpO2 < 80%)
Number of catheterisation
attempts
Requirement for, and duration of,
positive pressure ventilation by mask
Duration of bradycardia (heart
rate < 100 beats per minute)
Incidence of apparent discomfortTrial plan
Australasian neonatal Units and selected international
centres, including those in the Vermont-Oxford network,
are being invited to join the trial, and local information
sessions held in interested centres as required. The Trial
Coordinating Centre Team assists Units joining the study
with ethics submissions and organisational matters.
At the time of study commencement at each site, a
trial workshop is being conducted by a team from the
Trial Coordinating Centre. These workshops consist of 1)
a formal outline of the trial, 2) a hands-on demonstration
of the MIST technique using an intubation mannequin, 3)
a bedside simulation of the MIST procedure and of the
sham intervention by an OPTIMIST Treatment Team,
and 4) in-depth discussion of the practicalities of screen-
ing, randomisation and data collection.
A full complement of participating centres is expected
for the OPTIMIST-A trial by mid-2015. Recruitment will
thereafter proceed at full rate until completion, which is
estimated to be completed at the end of 2017.
Data and safety monitoring committee
An independent Data and Safety Monitoring Committee
(DSMC) has been established for the OPTIMIST-A trial.
The terms of reference for this committee includes per-
formance of interim data analysis, periodic examination
of emerging external evidence in relation to MIST, and
monitoring of adverse events, compliance with the trial
protocol, and progress of recruitment. The DSMC has
Table 3 Selected outcomes from the OPTIMIST-A
follow-up study
Number of hospitalisations in the first
2 years
Major disability at 2 years
Number of hospitalisations with
respiratory illness in the first 2 years
Death or major disability at
2 years
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and other activities [50].
Interim analyses
The Trial Steering Committee expects that there will be a
maximum of three interim analyses for the OPTIMIST-A
trial. Relevant event rates in enrolled infants will be com-
pared to the background rates in data from the RHH-
RWH preterm CPAP study, and recommendations for
change in sample size made if a substantial disparity is
noted. The odds ratios for major outcomes will be exam-
ined in the two randomisation groups. For this compari-
son the statistical approach will be conservative, with a
recommendation to cease the trial on efficacy grounds
only to be made in the presence of very strong interim
evidence. Later analyses will also include consideration of
whether there is an unequivocal lack of efficacy. At each
meeting of the DSMC the ethical position in relation to
further randomisation will be considered based on results
of other randomised controlled trials comparing MIST
with standard care (continuation of CPAP).
Adverse events
Serious adverse events (SAEs), including those leading to
death, prolonged hospitalisation or persistent disability,
are relatively common in preterm infants 25–28 weeks
gestation. Serious adverse events which are in the opinion
of the local investigator unexpected, are to be reported
within 5 working days to the coordinating centre. The
SAE will then be reported to the local Ethics Committee,
the Tasmania Health and Medical Ethics Committee, the
Trial Steering Committee, the DSMC, and, as appropriate,
the Therapeutic Goods Administration and/or other fed-
eral regulatory bodies. The data pertaining to the SAE will
be examined by the DSMC, and any recommendations
made will be disseminated to local investigators.
Funding
Funding has been obtained for commencement of the
OPTIMIST-A trial from the RHH Research Foundation
(for 2011 and 2012), and from the Australian NH&MRC
for the years 2013–2017. Chiesi Farmaceutici, Parma,
Italy has agreed to supply the surfactant at significantly
reduced cost. The trial sponsor is the Menzies Research
Institute Tasmania, and the trial insurer is Unimutual
Limited.Discussion
This trial is the next logical step in refining the care pro-
vided to preterm infants 25–28 weeks gestation. It will
be by far the largest randomised controlled trial investi-
gating MIST conducted to date, and in its own right will
have sufficient power to give definitive information about
the place of this therapy. The concept of MIST is exciting
because of the possibility that giving surfactant in this way
to preterm infants may improve respiratory outcomes in-
cluding duration of respiratory support and risk of BPD. A
reduction in the incidence of BPD in the 25–28 week in-
fants would represent a significant advance for this group,
in which the risk of BPD remains high, and leads in many
cases to chronic respiratory ill health in infancy.
Endnote
aOPTIMIST-A: The first of a pair of clinical trials inves-
tigating MIST in preterm infants at different gestation
ranges (25–28 and 29–32 weeks). The acronym is derived
from Collaborative Paired Trials Investigating Minimally-
Invasive Surfactant Therapy.
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